Crédit Industriel et Commercial’s Catalyst Pharmaceutical CPRX Stock Holding History

Crédit Industriel et Commercial’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.08M	Buy	+193,503	New	+$5.71M	0.39%	59

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

CWP

Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CNAM

Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return

CCM

Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Crédit Industriel et Commercial's CPRX Position: Q2 2026 in Review

Crédit Industriel et Commercial opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 193,503 shares worth $6.08M. The stake represents 0.39% of the portfolio and ranks #59 among its holdings.

75 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Crédit Industriel et Commercial held 193,503 shares of Catalyst Pharmaceutical worth $6.08M as of Q2 2026.
Catalyst Pharmaceutical was a new Crédit Industriel et Commercial position in Q2 2026.
Catalyst Pharmaceutical made up 0.39% of Crédit Industriel et Commercial's portfolio in Q2 2026, its #59 holding.
75 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Crédit Industriel et Commercial's 13F filing for Q2 2026, filed 24 Jul 2026.